These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25249180)

  • 41. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
    Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
    J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
    Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advancements in the Development of non-BET Bromodomain Chemical Probes.
    Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
    ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
    Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
    J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
    Braun T; Gardin C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.
    Bamborough P; Chung CW; Furze RC; Grandi P; Michon AM; Watson RJ; Mitchell DJ; Barnett H; Prinjha RK; Rau C; Sheppard RJ; Werner T; Demont EH
    J Med Chem; 2018 Sep; 61(18):8321-8336. PubMed ID: 30226378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
    Fidanze SD; Liu D; Mantei RA; Hasvold LA; Pratt JK; Sheppard GS; Wang L; Holms JH; Dai Y; Aguirre A; Bogdan A; Dietrich JD; Marjanovic J; Park CH; Hutchins CW; Lin X; Bui MH; Huang X; Wilcox D; Li L; Wang R; Kovar P; Magoc TJ; Rajaraman G; Albert DH; Shen Y; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1804-1810. PubMed ID: 29678460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. I-BET726 suppresses human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Liu Z; Li P; Yang YQ; Cai S; Lin X; Chen MB; Guo H
    Cell Death Dis; 2020 May; 11(5):318. PubMed ID: 32371868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
    Seal JT; Atkinson SJ; Aylott H; Bamborough P; Chung CW; Copley RCB; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Lindon M; Messenger C; Michon AM; Mitchell D; Preston A; Prinjha RK; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2020 Sep; 63(17):9093-9126. PubMed ID: 32702236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
    Noguchi-Yachide T; Sakai T; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2015 Mar; 23(5):953-9. PubMed ID: 25678016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.